Xeris Biopharma Reports Cortisol Normalization With Recorlev in Cushing's Syndrome Case Study

Bitget2026/10/15 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Xeris Biopharma announced a Recorlev case study showing normalized cortisol levels with improved cardiometabolic health in a patient with difficult-to-control diabetes.
The case study is scheduled for presentation at the Cardiometabolic Health Congress on October 15-16, 2026.
Gvoke research presented October 9, 2026, found a gap between clinicians’ awareness of ready-to-use glucagon prescribing guidelines and actual prescribing practices.
A real-world analysis characterizing hypothyroidism patients using levothyroxine treatment records and thyroid laboratory data will be presented November 6, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610150800BIZWIRE_USPR_____20261015_BW322412) on October 15, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Xeris Biopharma Reports Cortisol Normalization With Recorlev in Cushing's Syndrome Case Study

You may also like

Crypto prices